Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects with Psychosis Associated with Alzheimer’s Disease (ADEPT-3)

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-504151-27-00

Acronym

KAR-033

Enrollment

289

Registered

2024-02-05

Start date

2024-05-09

Completion date

Unknown

Last updated

2025-10-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psychosis associated with Alzheimer’s Disease

Brief summary

Incidence of TEAEs

Detailed description

Incidence of serious TEAEs Incidence of TEAEs leading to discontinuation of IMP

Interventions

DRUGKarXT

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Incidence of TEAEs	—

Secondary

Measure	Time frame
Incidence of serious TEAEs Incidence of TEAEs leading to discontinuation of IMP	—

Countries

Belgium, Bulgaria, Croatia, Czechia, France, Germany, Greece, Hungary, Italy, Poland, Portugal, Romania, Slovakia, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026